NASDAQ:IVVD Invivyd Q4 2024 Earnings Report $0.92 -0.04 (-4.24%) Closing price 04:00 PM EasternExtended Trading$0.92 +0.00 (+0.21%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Invivyd EPS ResultsActual EPS-$0.15Consensus EPS -$0.25Beat/MissBeat by +$0.10One Year Ago EPSN/AInvivyd Revenue ResultsActual Revenue$13.80 millionExpected Revenue$13.57 millionBeat/MissBeat by +$233.00 thousandYoY Revenue GrowthN/AInvivyd Announcement DetailsQuarterQ4 2024Date3/20/2025TimeBefore Market OpensConference Call DateThursday, March 20, 2025Conference Call Time8:00AM ETUpcoming EarningsInvivyd's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Invivyd Earnings HeadlinesBTIG Research Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)September 16, 2026 | americanbankingnews.comInvivyd to Participate in Upcoming September Investor ConferencesSeptember 8, 2026 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 23 at 1:00 AM | InvestorPlace (Ad)Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comInvivyd Names Chairman Marc Elia CEO, Adds New DirectorsSeptember 1, 2026 | rttnews.comInvivyd Names Marc Elia CEO, Adds New Independent Director as VYD2311 Phase 3 Studies Near CompletionSeptember 1, 2026 | quiverquant.comQSee More Invivyd Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email. Email Address About InvivydInvivyd (NASDAQ:IVVD) is a biotechnology company focused on developing antibody-based medicines designed to protect against rapidly evolving viral diseases. The company uses its antibody discovery and engineering platform to create therapies intended to maintain activity as viruses mutate and to provide durable protection for people who may not be adequately protected by vaccines. Invivyd’s lead product is pemivibart, marketed in the United States as Pemgarda. Pemivibart is an intravenously administered monoclonal antibody authorized by the U.S. Food and Drug Administration for the pre-exposure prevention of COVID-19 in certain adults and adolescents who are moderately to severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination. The company continues to evaluate pemivibart and additional antibody candidates against emerging SARS-CoV-2 variants. The company was formerly known as Adagio Therapeutics and changed its name to Invivyd in 2023. Invivyd is headquartered in Waltham, Massachusetts, and its activities have primarily centered on the development and potential commercialization of antibody-based infectious-disease treatments in the United States.View Invivyd ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
